Hans Michelsensgatan 10
Box 48
Malmö 201 20
Sweden
46 1 03 35 45 00
https://www.arjo.com/int/
Settore/i:
Settore:
Impiegati a tempo pieno: 6.500
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Mr. Joacim Lindoff | CEO, President & Director | 17,05M | N/D | 1973 |
Mr. Niclas Sjosward | Chief Financial Officer | N/D | N/D | 1974 |
Jonas Cederhage | Executive Vice President of Product Development, Supply Chain & Operations | N/D | N/D | 1971 |
Sara Ehinger | Vice President of Investor Relations & Corporate Communications | N/D | N/D | N/D |
Ms. Ingrid Carlsson | Executive VP of Legal & Business Compliance and Board Secretary | N/D | N/D | 1976 |
Ms. Marianne Nilsson | Executive Vice President of Communication & Public Relations | N/D | N/D | 1982 |
Mr. Christian Stentoft | President of Global Sales & Service | N/D | N/D | 1984 |
Mr. Tobias Kramer | Executive Vice President of Global Marketing | N/D | N/D | 1984 |
Ms. Marion Gullstrand | Executive Vice President of Human Resources & Sustainability | N/D | N/D | 1957 |
Ms. Katarzyna Bobrow | Executive Vice President of Quality & Regulatory Compliance | N/D | N/D | 1980 |
Arjo AB (publ) develops and sells medical devices and solutions for patients for clinical and financial outcomes for healthcare in Europe, Asia and Pacific, South America, Africa, and internationally. It offers products and solutions for patient handling, hygiene, disinfection, medical beds, pressure injury prevention, diagnostics, prevention of deep vein thrombosis and treatment of edema, leg ulcer treatment and prevention, and for obstetric and cardiac diagnostics. The company also provides dementia and bariatric room assessment solutions, prone positioning early mobility, and rehabilitation services, as well as maintenance, and equipment rental and financing solutions. It serves private and public institutions that provide acute and long-term care. Arjo AB (publ) was founded in 1957 and is headquartered in Malmö, Sweden.
L'ISS Governance QualityScore di Arjo AB (publ) al 1 maggio 2024 è 10. I criteri di valutazione fondamentali sono revisione: 5; Consiglio di Amministrazione: 9; diritti degli azionisti: 8; retribuzione: 7.